Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.

Ex Output:
Eli Lilly drops inhaled insulin program.


Ex Input:
Publishing a study that found risk score tools are only around 46 percent accurate on how likely psychopathic convicts are to kill, rape or assault again, they said probation officers and judges should set little or no store by such tests. They warned that clinicians carrying out such classifications must be aware of their severe limitations, and make sure prisoners undergo comprehensive psychiatric diagnosis before any risks assessment is made. “If you apply these (tests) to somebody who is a psychopath, they’re utterly useless, you might as well toss a coin,” said Jeremy Coid, director of the forensic psychiatry research unit at Queen Mary University of London who led the study. “They will not predict accurately at all,” he told reporters at a briefing in London about his findings. Coid and other forensic psychiatrists say the findings - which also showed the tools perform only moderately well in prisoners with disorders like schizophrenia, depression, drug and alcohol dependence - could have major implications for risk assessment in criminal justice systems. “There are increasing expectations of public protection from violent behavior, and psychiatrists can be seriously criticized if they make wrong decisions,” he said. Seena Fazel, a consultant forensic psychiatrist at Britain’s University of Oxford, said the reliability of the tests’ predictive ability was so low that it might be best not to use them at all - and warned that at the very least, their results should only be noted by parole boards, rather than acted upon. “If you’re going to use these instruments, be aware of their strengths and limitations,” he told reporters. The estimated prevalence of adult psychopathy in the general population is around 1 percent, but that rises to between 15 percent and 25 percent among men in prison. Coid, whose study was published in the British Journal of Psychiatry, analyzed data from 1,396 male prisoners in England and Wales who were interviewed between six and 12 months before their release. All the men were serving sentences of two or more years for a sexual or violent offences. The prisoners were assessed for personality disorders, symptoms of schizophrenia, depression and drug and alcohol dependence, as well as being measured for psychopathy on a reputable scale known as Hare Psychopathy Check List. After their release, data on their re-offending rates was added to the study, and showed that among three different re-offending risk assessment tools used before their release, the accuracy among psychopaths was below 50 percent. While the tools were more accurate in predictions for prisoners with no mental health disorders - at around 75 percent accuracy - they were only around 60 percent right when it came to prisoners diagnosed with schizophrenia and depression. For prisoners with anti-social personality disorders the predictive value of the tests ranged from poor to little more than chance, with an average 53.2 percent predictive accuracy. And for the 70 prisoners rated as psychopathic, none of the tests was statistically better than chance. Coid said the results suggest it is time to question the expectations put on psychiatrists and psychologists asked to forecast future behavior of offenders, and to consider what can happen to their reputations if predictions are wrong. “The easy solution is to be highly restrictive on who is released, and be risk averse. However, even for serious offenders, most will be released at some stage and someone has to carry out a risk assessment,” he said. “We need to prioritize the development of new assessment tools for these hard-to-predict groups.”

Ex Output:
Predicting violence in psychopaths is 'no more than chance'.


Ex Input:
"As new coronavirus cases continue to rise across the country, public health officials have advised Americans to consider voting by mail this fall. But funding for the U.S. Postal Service is up in the air, and the USPS has warned states that it can’t guarantee all mail-in ballots will be counted in time for the November election. The White House isn’t helping. In an Aug. 13 interview with Fox News, President Donald Trump said he opposed including additional funding for the Postal Service — which has lost billions of dollars during the pandemic — in new coronavirus bailout legislation. Why? Because Democrats want to expand voting by mail. ""They want three and a half billion dollars for the mail-in votes,"" Trump said. ""They want $25 billion, billion, for the post office. Now they need that money in order to make the post office work so it can take all of these millions and millions of ballots."" ""But if they don't get those two items that means you can't have universal mail-in voting because you, they're not equipped to have it."" House Speaker Nancy Pelosi called lawmakers back early from their August recess to vote on legislation that would block the USPS from making operational changes. Trump has long derided the USPS as a waste of federal dollars. But an Aug. 12 ad from an anti-Trump political action committee claimed there may be ulterior motivations for the administration’s comments. ""This is Trump’s new postmaster general, Louis DeJoy,"" says a narrator in the ad, which was published by Really American on Twitter. ""A longtime Republican donor, DeJoy has given over $400,000 to Republicans just this year. Coincidentally, DeJoy and his wife have between $30 and $75 million in assets of direct competitors to the United States Postal Service."" ""That’s right — they own the competition. The man Trump put in charge of our post office has the most to gain from its destruction."" NEW VIDEO: Trump didn't choose Louis Dejoy to run the Post Office. He chose him to destroy it. #TrumpKillsUSPS pic.twitter.com/OOhJNOSnit The ad has more than 4 million views on Twitter, and similar claims have circulated widely on social media, according to CrowdTangle, a social media insights tool. But are they accurate? We reached out to the postmaster general’s office for a comment, but we haven’t heard back. We also haven’t heard back from Really American. So we dug into DeJoy’s financial records ourselves. We found that the postmaster general has donated more than $440,000 to Republican causes in 2020. DeJoy’s investments in USPS competitors are less certain, but government documents suggest he could own more than $75 million in assets. DeJoy was appointed postmaster general in May. Government documents show that he and his wife have tens of millions of dollars invested in companies that provide services similar to the USPS. DeJoy is the former chairman and CEO of New Breed Logistics, a contract logistics firm in North Carolina. The company helped the USPS process mail for more than 25 years. In 2014, DeJoy sold the company to XPO Logistics, Inc., for $615 million. XPO says it’s a ""top 10 global provider of transportation and logistics services"" and is valued at more than $7.5 billion. As part of the 2014 deal, DeJoy joined the board of XPO and agreed to use $30 million of his proceeds to buy restricted stock in the company. That brings us to the low point of the range mentioned in Really American’s ad. But what about the rest of the purported assets? DeJoy is married to Aldona Wos, a former U.S. ambassador to Estonia who has been nominated to serve as ambassador to Canada. The Washington Post reported in June that DeJoy and Wos hold ""between $30.1 million and $75.3 million in assets in USPS competitors or contractors, according to Wos’ financial disclosure paperwork filed with the Office of Government Ethics."" A fact-check from USA Today estimated that the couple may have up to $75.8 million in assets. We requested Wos’ 85-page financial disclosure from the Office of Government Ethics to see for ourselves. Here’s a breakdown of Wos and DeJoy’s assets in logistics companies, as of 2019: XPO: $30.2-$75.5 million United Parcel Service: $115,002-$300,000 J.B. Hunt Transport Services Inc.: $1,001-$15,000 Forward Air Corp.: $1,001-$15,000 Saia Inc.: $1,001-$15,000 The vast majority of DeJoy and Wos’ holdings are in XPO. However, whether or not XPO is a ""direct competitor"" to the USPS, as Really American claimed, is up for at least a little debate. A 2019 Securities and Exchange Commission filing indicates that, as of 2018, XPO’s ""peer group"" companies included UPS and J.B. Hunt. The Postal Service is not mentioned in the filing, but since XPO arranges more than 10 million last-mile deliveries per year, the company could benefit from a weakened USPS. Really American is correct to say that DeJoy has a financial interest in companies that provide services similar to the USPS. But is the postmaster general also a Republican donor, as the PAC claims? In a word: yes. According to the Federal Election Commission, DeJoy has contributed more than $440,000 to Republican causes since January 2020. Those causes include the Trump Victory committee, the North Carolina Republican Party, the National Republican Senatorial Committee and the (Rep. Kevin) McCarthy Victory Fund. Congressional Democrats questioned DeJoy’s political and business ties soon after he was appointed in May. CNN reported Aug. 14 that the USPS inspector general is investigating DeJoy for potential ethics conflicts and reviewing some of his policy changes, such as eliminating overtime and slowing some mail delivery. We reached out to the Louis DeJoy and Aldona Wos Family Foundation for a comment, but we haven’t heard back. In an ad, Really American said DeJoy ""gave $400,000 to Republicans just this year"" and has ""between $30 and $75 million in assets of direct competitors to the United States Postal Service."" Data from the Federal Election Commission and the Office of Government Ethics confirms those claims. DeJoy and Wos’ holdings in XPO and UPS alone amount to between $30.3 and $75.8 million, and DeJoy has contributed more than $440,000 to Republican causes since January 2020. Whether XPO is a ""direct competitor"" to the USPS is up for debate, but the company could benefit from a weaker Postal Service. Meanwhile, the USPS inspector general is investigating DeJoy for potential ethics conflicts. The Really American ad is accurate but needs clarification or additional information.."

Ex Output:

Postmaster General Louis DeJoy “gave $400,000 to Republicans just this year” and has “between $30 and $75 million in assets of direct competitors to the United States Postal Service.”